Expansion into Canada: Recent chatter on social media has focused on Hims & Hers Health's expansion into the Canadian market following their acquisition of Livewell, a digital health platform. Many are optimistic about the company’s potential to disrupt healthcare access with affordable, personalized care in new regions. This move is seen as a strategic step to bolster their global presence.
Stock Price Volatility: Discussions also highlight the stock’s recent price fluctuations, with some noting a significant drop from its 52-week high. There’s a split in opinions, with some viewing the current price as a buying opportunity, while others express concern over regulatory challenges and market reassessment of telemedicine growth. The volatility keeps the conversation lively and polarized.
Future Growth Potential: A recurring theme is the company’s long-term outlook, with enthusiastic predictions about Hims & Hers becoming a leader in digital healthcare. Posts often mention revenue growth and subscriber increases as key drivers, though concerns about profit margins and regulatory hurdles linger. The blend of bold forecasts and cautious takes fuels ongoing debate.
Note: This discussion summary was generated from an AI condensation of post data.
Hims & Hers Health Insider Trading Activity
Hims & Hers Health insiders have traded $HIMS stock on the open market 64 times in the past 6 months. Of those trades, 0 have been purchases and 64 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 24 sales selling 1,252,093 shares for an estimated $62,715,056.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 12 sales selling 369,372 shares for an estimated $19,669,723.
- MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 10 sales selling 77,349 shares for an estimated $4,288,956.
- PATRICK HARRISON CARROLL (Chief Medical Officer) has made 0 purchases and 3 sales selling 80,042 shares for an estimated $4,088,809.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 11 sales selling 28,675 shares for an estimated $1,419,687.
- IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 16,821 shares for an estimated $733,472.
- DEBORAH M. AUTOR (Chief Policy Officer) sold 7,054 shares for an estimated $258,952
- GARCIA ANDREA G PEREZ sold 2,500 shares for an estimated $97,925
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Hims & Hers Health Revenue
Hims & Hers Health had revenues of $599M in Q3 2025. This is an increase of 49.16% from the same period in the prior year.
You can track HIMS financials on Quiver Quantitative's HIMS stock page.
Hims & Hers Health Congressional Stock Trading
Members of Congress have traded $HIMS stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 08/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Hims & Hers Health Hedge Fund Activity
We have seen 303 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 288 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 15,045,710 shares (+549.0%) to their portfolio in Q3 2025, for an estimated $853,392,671
- SRS INVESTMENT MANAGEMENT, LLC removed 4,000,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $226,880,000
- TIDAL INVESTMENTS LLC added 2,707,111 shares (+1779.6%) to their portfolio in Q3 2025, for an estimated $153,547,335
- FARALLON CAPITAL MANAGEMENT LLC added 2,533,271 shares (+30.8%) to their portfolio in Q3 2025, for an estimated $143,687,131
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,504,252 shares (+444.1%) to their portfolio in Q3 2025, for an estimated $142,041,173
- RENAISSANCE TECHNOLOGIES LLC added 2,227,400 shares (+32.4%) to their portfolio in Q3 2025, for an estimated $126,338,128
- D. E. SHAW & CO., INC. removed 1,886,971 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $107,028,995
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Hims & Hers Health Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/04/2025
- B of A Securities issued a "Underperform" rating on 11/04/2025
- Canaccord Genuity issued a "Buy" rating on 09/12/2025
To track analyst ratings and price targets for Hims & Hers Health, check out Quiver Quantitative's $HIMS forecast page.
Hims & Hers Health Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 5 analysts offer price targets for $HIMS in the last 6 months, with a median target of $48.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $48.0 on 12/09/2025
- David Larsen from BTIG set a target price of $85.0 on 11/04/2025
- Allen Lutz from B of A Securities set a target price of $32.0 on 11/04/2025
- Maria Ripps from Canaccord Genuity set a target price of $68.0 on 09/12/2025
- Jailendra Singh from Truist Securities set a target price of $37.0 on 08/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
